(Q46033944)

English

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

scientific article published on 28 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

7

object named as

Thomas Otto

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

author name string

Holger Gerullis

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Lothar Bergmann

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Luise Maute

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Thorsten Holger Ecke

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Christoph Eimer

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Jens Willem Bagner

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

publication date

28 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

27

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

373-378

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

https://scigraph.springernature.com/pub.10.1007/s12032-009-9220-1

0 references

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus in renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma guideline

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EORTC-GU group expert opinion on metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2007

1 reference

https://pubmed.ncbi.nlm.nih.gov/19399651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-009-9220-1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399651

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46033944&oldid=1927775136"